U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C4H9NO2
Molecular Weight 103.1198
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of .GAMMA.-AMINOBUTYRIC ACID

SMILES

NCCCC(O)=O

InChI

InChIKey=BTCSSZJGUNDROE-UHFFFAOYSA-N
InChI=1S/C4H9NO2/c5-3-1-2-4(6)7/h1-3,5H2,(H,6,7)

HIDE SMILES / InChI

Molecular Formula C4H9NO2
Molecular Weight 103.1198
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

γ-aminobutyric acid (GABA), a naturally occurring substance, which is a product of decarboxylation of the amino acid glutamate mediated by the synthesizing enzyme glutamic acid decarboxylase. GABA is a major inhibitory neurotransmitter of the brain and acts mainly through the GABAA receptor (GABAAR). GABA is locally produced by the pancreatic beta cells. GABAARs are also expressed in various immune cells, including T-cells, peripheral blood mononuclear cells, and are known to exert immune-inhibitory effects. Recently was studied, that GABA has the potential in treatment of Type I Diabetes. Moreover, was shown, that GABA administration could enhance immunity under stress conditions.

Originator

Curator's Comment: -Aminobutyric acid (GABA) was initially identified as a major inhibitory neurotransmitter in the brain by Roberts and Frankel in 1950

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
200.0 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Preventing
THERAPENTIN-90

Approved Use

Gabapentin Capsules is indicated as adjunctive therapy in the treatment of partial seizures with and without secondary generalization in patients over 12 years of age with epilepsy. Gabapentin Capsules is also indicated as adjunctive therapy in the treatment of partial seizures in pediatric patients age 3 – 12 years.

Launch Date

2011
Primary
Gammalon

Approved Use

Gamma-aminobutyric acid helps to restore the metabolism of the brain: activates energy processes, improves glucose utilization and blood supply, increases the respiratory activity of tissues. GABA has a mild psychostimulant effect, has anticonvulsant activity, stabilizes high blood pressure, improves memory, increases the productivity of thinking, helps restore speech and movements after disorders of cerebral circulation. Given these properties of the active substance, Gammalon is prescribed for adult patients with: Vascular diseases of the brain (damage of cerebral vessels, atherosclerosis, caused by hypertension), especially in cases when they are accompanied by sleep disorders, headache, dizziness; Atherosclerosis of cerebral arteries with concomitant phenomena of softening of the brain; Conditions after cerebrovascular accident, stroke, traumatic brain injury; Chronic cerebrovascular insufficiency, dyscirculatory encephalopathy, characterized by impaired attention, memory and speech, headaches and dizziness; Symptom complex of motion sickness (sea, air sickness); Alcohol encephalopathy; Alcoholic polyneuritis. In pediatrics, Gammalon, according to the instructions, is used for: Cerebral palsy; Lag of mental development, accompanied by reduced mental activity; Consequences of birth and / or craniocerebral trauma; Symptom complex of motion sickness.
Primary
Gammalon

Approved Use

Gamma-aminobutyric acid helps to restore the metabolism of the brain: activates energy processes, improves glucose utilization and blood supply, increases the respiratory activity of tissues. GABA has a mild psychostimulant effect, has anticonvulsant activity, stabilizes high blood pressure, improves memory, increases the productivity of thinking, helps restore speech and movements after disorders of cerebral circulation. Given these properties of the active substance, Gammalon is prescribed for adult patients with: Vascular diseases of the brain (damage of cerebral vessels, atherosclerosis, caused by hypertension), especially in cases when they are accompanied by sleep disorders, headache, dizziness; Atherosclerosis of cerebral arteries with concomitant phenomena of softening of the brain; Conditions after cerebrovascular accident, stroke, traumatic brain injury; Chronic cerebrovascular insufficiency, dyscirculatory encephalopathy, characterized by impaired attention, memory and speech, headaches and dizziness; Symptom complex of motion sickness (sea, air sickness); Alcohol encephalopathy; Alcoholic polyneuritis. In pediatrics, Gammalon, according to the instructions, is used for: Cerebral palsy; Lag of mental development, accompanied by reduced mental activity; Consequences of birth and / or craniocerebral trauma; Symptom complex of motion sickness.
Primary
Gammalon

Approved Use

Gamma-aminobutyric acid helps to restore the metabolism of the brain: activates energy processes, improves glucose utilization and blood supply, increases the respiratory activity of tissues. GABA has a mild psychostimulant effect, has anticonvulsant activity, stabilizes high blood pressure, improves memory, increases the productivity of thinking, helps restore speech and movements after disorders of cerebral circulation. Given these properties of the active substance, Gammalon is prescribed for adult patients with: Vascular diseases of the brain (damage of cerebral vessels, atherosclerosis, caused by hypertension), especially in cases when they are accompanied by sleep disorders, headache, dizziness; Atherosclerosis of cerebral arteries with concomitant phenomena of softening of the brain; Conditions after cerebrovascular accident, stroke, traumatic brain injury; Chronic cerebrovascular insufficiency, dyscirculatory encephalopathy, characterized by impaired attention, memory and speech, headaches and dizziness; Symptom complex of motion sickness (sea, air sickness); Alcohol encephalopathy; Alcoholic polyneuritis. In pediatrics, Gammalon, according to the instructions, is used for: Cerebral palsy; Lag of mental development, accompanied by reduced mental activity; Consequences of birth and / or craniocerebral trauma; Symptom complex of motion sickness.
PubMed

PubMed

TitleDatePubMed
gamma-Aminobutyric acid in brain: its formation from glutamic acid.
1950 Nov
Mechanisms of action of antiepileptic drugs.
2005
Glutamate- and GABA-based CNS therapeutics.
2006 Feb
Gamma-aminobutyric acid (GABA) stimulates pancreatic cancer growth through overexpressing GABAA receptor pi subunit.
2007 Oct 15
GABAergic system in the endocrine pancreas: a new target for diabetes treatment.
2015
Neurotransmitters as food supplements: the effects of GABA on brain and behavior.
2015
Patents

Patents

Sample Use Guides

Patients will receive the Active GABA (Gamma-Amino Butyric Acid) capsules. Each capsule 250mg. Dosage will be calculated according to body surface area of the child and divided between 2 meals/day. Larger dose taken with larger meal.
Route of Administration: Oral
The HEK293 cells constitutively expressing exogenous GABA receptor π subunit (GABRP) revealed the growth-promoting effect of GABA treatment (serial concentrations: 0, 1, 10, 100 μmol/L);for 6 d). GABA treatment stimulated GABRP-positive pancreatic ductal adenocarcinoma (PDAC) cell proliferatio and activated the mitogen-activated protein kinase/extracellular signal–regulated kinase (MAPK/Erk) cascade. These findings imply that GABA and GABRP could play important roles in PDAC development and progression, and that this pathway can be a promising molecular target for the development of new therapeutic strategies for PDAC.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:13:21 GMT 2023
Edited
by admin
on Fri Dec 15 15:13:21 GMT 2023
Record UNII
2ACZ6IPC6I
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
.GAMMA.-AMINOBUTYRIC ACID
MI  
Systematic Name English
4-AMINOBUTANOIC ACID
Systematic Name English
AMINOBUTYRIC ACID, GAMMA-
Common Name English
.GAMMA.-AMINO-BUTYRIC ACID
Common Name English
GABA
Common Name English
4-AMINOBUTYRIC ACID [FHFI]
Common Name English
AMINOBUTYRIC ACID
INCI  
INCI  
Official Name English
SODIUM ALENDRONATE TRIHYDRATE IMPURITY A [EP IMPURITY]
Common Name English
GAMMA-AMINOBUTYRATE
Systematic Name English
PIPERIDIC ACID
Systematic Name English
GAMMA-AMINOBUTYRIC ACID [MART.]
Common Name English
.GAMMA.-AMINO-N-BUTYRIC ACID
Common Name English
NSC-27418
Code English
VIGABATRIN IMPURITY D [EP IMPURITY]
Common Name English
BUTYRIC ACID, 4-AMINO-
Common Name English
AMINOBUTYRATE
Systematic Name English
Gamma-aminobutyric acid [WHO-DD]
Common Name English
.GAMMA.-AMINOBUTYRIC ACID [MI]
Common Name English
VIGABATRIN IMPURITY, .GAMMA.-AMINOBUTYRIC ACID- [USP IMPURITY]
Common Name English
FACTOR I
Common Name English
GAMMA-AMINOBUTYRIC ACID
JAN   MART.   USP-RS   WHO-DD  
Systematic Name English
GAMMA-AMINOBUTYRIC ACID [USP-RS]
Common Name English
GAMMA-AMINOBUTYRIC ACID [JAN]
Common Name English
AMINOBUTYRIC ACID [INCI]
Common Name English
Classification Tree Code System Code
DSLD 443 (Number of products:610)
Created by admin on Fri Dec 15 15:13:21 GMT 2023 , Edited by admin on Fri Dec 15 15:13:21 GMT 2023
WHO-VATC QN03AG03
Created by admin on Fri Dec 15 15:13:21 GMT 2023 , Edited by admin on Fri Dec 15 15:13:21 GMT 2023
WHO-ATC N03AG03
Created by admin on Fri Dec 15 15:13:21 GMT 2023 , Edited by admin on Fri Dec 15 15:13:21 GMT 2023
EPA PESTICIDE CODE 30802
Created by admin on Fri Dec 15 15:13:21 GMT 2023 , Edited by admin on Fri Dec 15 15:13:21 GMT 2023
JECFA EVALUATION 4-AMINOBUTYRIC ACID
Created by admin on Fri Dec 15 15:13:21 GMT 2023 , Edited by admin on Fri Dec 15 15:13:21 GMT 2023
NCI_THESAURUS C687
Created by admin on Fri Dec 15 15:13:21 GMT 2023 , Edited by admin on Fri Dec 15 15:13:21 GMT 2023
Code System Code Type Description
GRAS Notification (GRN No.)
257
Created by admin on Fri Dec 15 15:13:21 GMT 2023 , Edited by admin on Fri Dec 15 15:13:21 GMT 2023
PRIMARY
WIKIPEDIA
GAMMA-AMINOBUTYRIC ACID
Created by admin on Fri Dec 15 15:13:21 GMT 2023 , Edited by admin on Fri Dec 15 15:13:21 GMT 2023
PRIMARY
ECHA (EC/EINECS)
200-258-6
Created by admin on Fri Dec 15 15:13:21 GMT 2023 , Edited by admin on Fri Dec 15 15:13:21 GMT 2023
PRIMARY
SMS_ID
100000078174
Created by admin on Fri Dec 15 15:13:21 GMT 2023 , Edited by admin on Fri Dec 15 15:13:21 GMT 2023
PRIMARY
GRAS Notification (GRN No.)
595
Created by admin on Fri Dec 15 15:13:21 GMT 2023 , Edited by admin on Fri Dec 15 15:13:21 GMT 2023
PRIMARY
MESH
D005680
Created by admin on Fri Dec 15 15:13:21 GMT 2023 , Edited by admin on Fri Dec 15 15:13:21 GMT 2023
PRIMARY
RS_ITEM_NUM
1020023
Created by admin on Fri Dec 15 15:13:21 GMT 2023 , Edited by admin on Fri Dec 15 15:13:21 GMT 2023
PRIMARY
RXCUI
618771
Created by admin on Fri Dec 15 15:13:21 GMT 2023 , Edited by admin on Fri Dec 15 15:13:21 GMT 2023
ALTERNATIVE
RXCUI
70582
Created by admin on Fri Dec 15 15:13:21 GMT 2023 , Edited by admin on Fri Dec 15 15:13:21 GMT 2023
ALTERNATIVE
EPA CompTox
DTXSID6035106
Created by admin on Fri Dec 15 15:13:21 GMT 2023 , Edited by admin on Fri Dec 15 15:13:21 GMT 2023
PRIMARY
RXCUI
4617
Created by admin on Fri Dec 15 15:13:21 GMT 2023 , Edited by admin on Fri Dec 15 15:13:21 GMT 2023
PRIMARY
NCI_THESAURUS
C80523
Created by admin on Fri Dec 15 15:13:21 GMT 2023 , Edited by admin on Fri Dec 15 15:13:21 GMT 2023
PRIMARY
FDA UNII
2ACZ6IPC6I
Created by admin on Fri Dec 15 15:13:21 GMT 2023 , Edited by admin on Fri Dec 15 15:13:21 GMT 2023
PRIMARY
NSC
27418
Created by admin on Fri Dec 15 15:13:21 GMT 2023 , Edited by admin on Fri Dec 15 15:13:21 GMT 2023
PRIMARY
RXCUI
618257
Created by admin on Fri Dec 15 15:13:21 GMT 2023 , Edited by admin on Fri Dec 15 15:13:21 GMT 2023
ALTERNATIVE
CHEBI
16865
Created by admin on Fri Dec 15 15:13:21 GMT 2023 , Edited by admin on Fri Dec 15 15:13:21 GMT 2023
PRIMARY
DAILYMED
2ACZ6IPC6I
Created by admin on Fri Dec 15 15:13:21 GMT 2023 , Edited by admin on Fri Dec 15 15:13:21 GMT 2023
PRIMARY
JECFA MONOGRAPH
1749
Created by admin on Fri Dec 15 15:13:21 GMT 2023 , Edited by admin on Fri Dec 15 15:13:21 GMT 2023
PRIMARY
MERCK INDEX
m1695
Created by admin on Fri Dec 15 15:13:21 GMT 2023 , Edited by admin on Fri Dec 15 15:13:21 GMT 2023
PRIMARY Merck Index
DRUG CENTRAL
1262
Created by admin on Fri Dec 15 15:13:21 GMT 2023 , Edited by admin on Fri Dec 15 15:13:21 GMT 2023
PRIMARY
EVMPD
SUB127282
Created by admin on Fri Dec 15 15:13:21 GMT 2023 , Edited by admin on Fri Dec 15 15:13:21 GMT 2023
PRIMARY
ChEMBL
CHEMBL96
Created by admin on Fri Dec 15 15:13:21 GMT 2023 , Edited by admin on Fri Dec 15 15:13:21 GMT 2023
PRIMARY
DRUG BANK
DB02530
Created by admin on Fri Dec 15 15:13:21 GMT 2023 , Edited by admin on Fri Dec 15 15:13:21 GMT 2023
PRIMARY
PUBCHEM
119
Created by admin on Fri Dec 15 15:13:21 GMT 2023 , Edited by admin on Fri Dec 15 15:13:21 GMT 2023
PRIMARY
CAS
56-12-2
Created by admin on Fri Dec 15 15:13:21 GMT 2023 , Edited by admin on Fri Dec 15 15:13:21 GMT 2023
PRIMARY
EVMPD
SUB13946MIG
Created by admin on Fri Dec 15 15:13:21 GMT 2023 , Edited by admin on Fri Dec 15 15:13:21 GMT 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
TARGET -> AGONIST
Binding Assay
IC50
TARGET -> AGONIST
SALT/SOLVATE -> PARENT
Related Record Type Details
PRODRUG -> METABOLITE ACTIVE
HELPS WITH PENETRATION TO CNS
Related Record Type Details
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
PARENT -> IMPURITY
Related Record Type Details
ACTIVE MOIETY